Milan, Nov 18. (Adnkronos Health) – November 19 marks World Pancreatic Cancer Day, among the most feared forms of cancer, which according to Aiom – Italian Association of Medical Oncology data, recorded approximately 13,585 new diagnoses in 2024. But what is the pancreas, why does it get sick, and what symptoms should you pay attention to? Humanitas experts explain it with ‘An answer today, new possibilities tomorrow’, an interactive initiative aimed at patients, caregivers, and professionals at the Rozzano hospital (Milan). An opportunity to learn more about the work of the Pancreas Unit and the research projects that the IRCCS is carrying out, also thanks to 5×1000 funds. The appointment is for tomorrow at Humanitas, on the first floor of Building 2, from 9:30 AM to 4 PM.
The pancreas is a small organ, weighing about 80 grams, fundamental for many digestive and metabolic processes, describe the specialists of the Milanese institute. Among the pathologies that can affect it, pancreatic adenocarcinoma is one of the most aggressive and difficult forms of cancer to treat, also due to frequent diagnosis at an advanced stage. Among the main risk factors are advanced age, smoking, obesity, reduced physical activity, high consumption of alcohol and saturated fats, low intake of fresh vegetables and fruit, chronic pancreatitis, and diabetes. “Today we know that some categories of people are at higher risk of developing pancreatic cancer because they belong to families where there are multiple cases of this neoplasm, or because they carry mutations involved in the development of pancreatic cancer – states Silvia Carrara, head of the Diagnostic and Therapeutic Ecoendoscopy section of the IRCCS Humanitas Clinical Institute, President-elect of the European Pancreatic Club (Epv) – The identification of at-risk individuals and surveillance conducted with the right means can lead to early diagnoses and improved patient survival. In this direction, Panc-Genobio is inserted, a research project funded by the Pnrr Prevention Hub, which aims to improve the early diagnosis of pancreatic cancer in high-risk individuals, integrating ecoendoscopy with liquid biopsy that searches for biomarkers in the blood potentially associated with the presence of a tumor. The goal is to identify the disease in its initial stages, when treatment possibilities are greater.”
To detect pancreatic cancer, it is important to pay attention to some signs, including yellowing of the skin and eyes (jaundice), abdominal or back pain, unexplained loss of appetite or weight, persistent fatigue, changes in stool consistency that appear greasy and fatty (steatorrhea), and sudden onset of diabetes, experts list. “These symptoms are often confused with gastric or digestive problems, making diagnosis complex or late – highlights Alessandro Zerbi, head of Pancreatic Surgery at Humanitas – Furthermore, only 20% of patients diagnosed with pancreatic carcinoma are candidates for ‘curative’ surgery, with a 5-year survival rate of approximately 20-30%. The interventions are very complex due to the organ’s position deep in the abdomen, near important blood vessels and delicate structures. Therefore, it is fundamental for patients to access specialized centers with multidisciplinary pathways, clinical trials, and proven experience in treating the pathology.”
Humanitas’ Pancreas Unit, a specialized Hub accredited by the Lombardy Region, is committed to finding new answers for patients, adopting a multidisciplinary approach to ensure precise diagnoses and personalized pathways, thanks to sophisticated imaging tools, minimally invasive and robotic surgical techniques, radiotherapy protocols, and increasingly advanced medical and endoscopic treatments, a note recalls. Research programs are also active in the Pancreas Unit to improve knowledge of the disease and develop new therapeutic approaches.
“Today in Italy, chemotherapy treatments are available that are used both in the neoadjuvant and adjuvant phases, i.e., before and after surgery, and in advanced stages, when there is no indication for surgery – explains Lorenza Rimassa, head of Hepato-Biliary Pancreatic Oncology at the IRCCS Humanitas Clinical Institute – Research is focusing on the development of new drugs and targeted therapies, also for patients who cannot undergo surgery. After years of work, clinical research is making progress that we hope will soon translate into new therapies accessible to everyone.” Then there is radiotherapy, which “within the Pancreas Unit plays an important role in at least four groups of patients – emphasizes Marta Scorsetti, head of Radiotherapy and Radiosurgery at Humanitas – Primarily for patients with inoperable localized disease, even after chemotherapy. In oligometastatic disease, i.e., when there are limited metastases with a restricted number of lesions confined to one or a few organs. There is also palliative radiotherapy, which helps patients better manage symptoms. Finally, in case of recurrence after surgery and also after other cycles of radiotherapy, there is the opportunity to treat patients with protons.”
Another research direction is the improvement of techniques and tools available to surgeons. A concrete example is the pancreatic phantom, a three-dimensional artificial reproduction of the organ, created by researchers from Humanitas and Politecnico di Milano with the support of the 3D Innovation Lab of Humanitas University and the Humanitas Foundation for Research. By reproducing the anatomical structure and biomechanical properties of the organ, the model allows young surgeons and residents to practice in realistic conditions and enables the study and testing of new instruments and materials for pancreatic surgery, which is among the most difficult. “A project that demonstrates how collaboration between clinical, scientific, and technological expertise can contribute to innovating surgical practice for increasingly safe and targeted interventions.”